Evidence map›Paper›PMID 20064929›Full record

ArticleThe Journal of biological chemistry2010

P2Y2 nucleotide receptors mediate metalloprotease-dependent phosphorylation of epidermal growth factor receptor and ErbB3 in human salivary gland cells.

Ann M Ratchford, Olga J Baker, Jean M Camden, Shivaji Rikka, Michael J Petris, Cheikh I Seye, Laurie Erb, Gary A Weisman

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 1 pooled it
4.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Therapeutic potential for P2YPurinergic signalling · 2023
    Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. P2YArchives of oral biology · 2021
    Article
  10. Review
  11. Review
  12. P2YOral oncology · 2020
    Article
  13. Update of P2Y receptor pharmacology: IUPHAR Review 27.British journal of pharmacology · 2020
    Review
  14. Article
  15. Article
  16. Review
  17. P2Y2 purinergic receptor modulates virus yield, calcium homeostasis, and cell motility in human cytomegalovirus-infected cells.Proceedings of the National Academy of Sciences of the United States of America · 2019
    Article
  18. P2YOral diseases · 2018
    Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Ann M RatchfordDepartment of Biochemistry, University of Missouri, Christopher S. Bond Life Sciences Center, Columbia, Missouri 65211, USA.
Olga J Baker
Jean M Camden
Shivaji Rikka
Michael J Petris
Cheikh I Seye
Laurie Erb
Gary A Weisman
University of Missouri · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The G protein-coupled receptor P2Y(2) nucleotide receptor (P2Y(2)R) has been shown to be up-regulated in a variety of tissues in response to stress or injury. Recent studies have suggested that P2Y(2)Rs may play a role in immune responses, wound healing, and tissue regeneration via their ability to activate multiple signaling pathways, including activation of growth factor receptors. Here, we demonstrate that in human salivary gland (HSG) cells, activation of the P2Y(2)R by its agonist induces phosphorylation of ERK1/2 via two distinct mechanisms, a rapid, protein kinase C-dependent pathway and a slower and prolonged, epidermal growth factor receptor (EGFR)-dependent pathway. The EGFR-dependent stimulation of UTP-induced ERK1/2 phosphorylation in HSG cells is inhibited by the adamalysin inhibitor tumor necrosis factor-alpha protease inhibitor or by small interfering RNA that selectively silences ADAM10 and ADAM17 expression, suggesting that ADAM metalloproteases are required for P2Y(2)R-mediated activation of the EGFR. G protein-coupled receptors have been shown to promote proteolytic release of EGFR ligands; however, neutralizing antibodies to known ligands of the EGFR did not inhibit UTP-induced EGFR phosphorylation. Immunoprecipitation experiments indicated that UTP causes association of the EGFR with another member of the EGF receptor family, ErbB3. Furthermore, stimulation of HSG cells with UTP induced phosphorylation of ErbB3, and silencing of ErbB3 expression inhibited UTP-induced phosphorylation of both ErbB3 and EGFR. UTP-induced phosphorylation of ErbB3 and EGFR was also inhibited by silencing the expression of the ErbB3 ligand neuregulin 1 (NRG1). These results suggest that P2Y(2)R activation in salivary gland cells promotes the formation of EGFR/ErbB3 heterodimers and metalloprotease-dependent neuregulin 1 release, resulting in the activation of both EGFR and ErbB3.

Indexed as

ADAM10 ProteinADAM17 ProteinADAM ProteinsAmyloid Precursor Protein SecretasesAnimalsCells, CulturedEnzyme ActivationEnzyme InhibitorsErbB ReceptorsHumansMembrane ProteinsMetalloproteasesMiceMice, Inbred C57BLMice, KnockoutMitogen-Activated Protein Kinase 1ADAM10 ProteinADAM10 protein, humanADAM17 ProteinADAM17 protein, humanAdam17 protein, mouseADAM ProteinsAmyloid Precursor Protein SecretasesEnzyme InhibitorsErbB ReceptorsMembrane ProteinsMetalloproteasesMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3Neuregulin-1P2RY2 protein, humanP2ry2 protein, mousePurinergic P2 Receptor AgonistsQuinazolinesReceptor, ErbB-3Receptors, Purinergic P2Receptors, Purinergic P2Y2RNA, Small InterferingRTKI cpdTyrphostins

Identifiers

PMID20064929
PMCPMC2844202
OpenAlexW1967814569

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.